secwatch.observer — SEC 8-K summary
======================================

Issuer:     Maxpro Capital Acquisition Corp. (—)
CIK:        0001874259
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0001104659-23-038774
Event type: m_and_a
Sentiment:  positive
Materiality: 1.00
Item codes: 1.01, 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apollomics completes business combination with Maxpro, begins trading on Nasdaq under APLM/APLMW
--------------------------------------------------------------------------------

- Apollomics (APLM) and warrants (APLMW) start trading on Nasdaq March 30, 2023.
- $23.65M PIPE financing closed alongside the business combination.
- Apollomics pipeline includes 9 oncology drug candidates; vebreltinib Phase 2 results expected this year.
- Uproleselan Phase 3 patient recruitment in China expected to complete this year.
- Maxpro's securities delisted from Nasdaq; Maxpro becomes wholly owned subsidiary of Apollomics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1874259/000110465923038774/0001104659-23-038774-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1874259/000110465923038774/tm2310655d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-038774

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer